A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Cancer cells frequently harbor defects in DNA repair pathways, leading to genomic instability. This can foster tumorigenesis but also provides a weakness in the tumor that can be exploited therapeutically. Tumors with compromised ability to repair double-strand DNA breaks by homologous recombination, including those with defects in BRCA1 and BRCA2, are highly sensitive to blockade of the repair of DNA single-strand breaks via the inhibition of the enzyme poly(ADP) ribose polymerase. This provides the basis for a novel synthetic lethal approach to cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citationSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Self-citationAssociation of BRCA1 with Rad51 in Mitotic and Meiotic Cells
Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81847-4 · Cited by 1,459
Amé, J., Spenlehauer, C., & de Murcia, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,459
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Self-citationBrca1 Controls Homology-Directed DNA Repair
Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80202-6 · Cited by 1,245
Cited by
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Hoeijmakers, J. H. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804615 · Cited by 2,239
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Self-citationTriple-negative breast cancer: disease entity or title of convenience?
Carey, L., Winer, E., Viale, G., Cameron, D., & Gianni, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.154 · Cited by 783
Recent progress in the diagnosis and treatment of ovarian cancer
Jelovac, D., & Armstrong, D. K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20113 · Cited by 765
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Pommier, Y., O’Connor, M. J., & de Bono, J. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9246 · Cited by 739
Badve, S., Dabbs, D. J., Schnitt, S. J., Baehner, F. L., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. R., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.200 · Cited by 680
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 638
Self-citationIbrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
Histological types of breast cancer: How special are they?
Weigelt, B., Geyer, F. C., & Reis-Filho, J. S. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.004 · Cited by 572
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
Garrido-Laguna, I., & Hidalgo, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.53 · Cited by 565
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547
Beyond chemotherapy: targeted therapies in ovarian cancer
Yap, T. A., Carden, C. P., & Kaye, S. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2583 · Cited by 495
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., Brunet, J.-S., Akslen, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2132 · Cited by 489
Shen, Y., Rehman, F. L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C. J., Post, L. E., & Ashworth, A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1391 · Cited by 479
Self-citationGeyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.09.159 · Cited by 478
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 469
Self-citationDissecting the Heterogeneity of Triple-Negative Breast Cancer
Metzger-Filho, O., Tutt, A., de Azambuja, E., Saini, K. S., Viale, G., Loi, S., Bradbury, I., Bliss, J. M., Azim, H. A., Ellis, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2010 · Cited by 465
Histological and molecular types of breast cancer: is there a unifying taxonomy?
Weigelt, B., & Reis-Filho, J. S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.166 · Cited by 457
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214676 · Cited by 449
“Headache 31 (11) 1 (<1) 4 (6) 0 5 (8) 0 9 (7) 0”
InfluentialTargeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Costa, R. L. B., Han, H. S., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4697-y · Cited by 439
Genetic Interactions in Cancer Progression and Treatment
Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.03.020 · Cited by 426
Self-citationMaier, P., Hartmann, L., Wenz, F., & Herskind, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010102 · Cited by 414
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7401 · Cited by 398
DNA Damage/Repair Management in Cancers
Alhmoud, J. F., Woolley, J. F., Al Moustafa, A.-E., & Malki, M. I. (2020) · Cancers · doi:10.3390/cancers12041050 · Cited by 362
Banerjee, S., & Kaye, S. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2243 · Cited by 357
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 355
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
Lee, A., & Djamgoz, M. B. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.003 · Cited by 354
Translating cancer research into targeted therapeutics
de Bono, J. S., & Ashworth, A. (2010) · Nature · doi:10.1038/nature09339 · Cited by 335
Self-citationPredictive biomarkers: a paradigm shift towards personalized cancer medicine
La Thangue, N. B., & Kerr, D. J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.121 · Cited by 332
Sakai, W., Swisher, E. M., Jacquemont, C., Chandramohan, K. V., Couch, F. J., Langdon, S. P., Wurz, K., Higgins, J., Villegas, E., & Taniguchi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1178 · Cited by 321
Synthetic lethality: General principles, utility and detection using genetic screens in human cells
Nijman, S. M. B. (2011) · FEBS Letters · doi:10.1016/j.febslet.2010.11.024 · Cited by 319
Zarghooni, M., Bartels, U., Lee, E., Buczkowicz, P., Morrison, A., Huang, A., Bouffet, E., & Hawkins, C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5463 · Cited by 313
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells
Marcotte, R., Brown, K. R., Suarez, F., Sayad, A., Karamboulas, K., Krzyzanowski, P. M., Sircoulomb, F., Medrano, M., Fedyshyn, Y., Koh, J. L. Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0224 · Cited by 303
Kondrashova, O., Topp, M., Nesic, K., Lieschke, E., Ho, G.-Y., Harrell, M. I., Zapparoli, G. V., Hadley, A., Holian, R., Boehm, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05564-z · Cited by 296
Targeting DNA damage response in cancer therapy
Hosoya, N., & Miyagawa, K. (2014) · Cancer Science · doi:10.1111/cas.12366 · Cited by 294
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
Moschetta, M., George, A., Kaye, S. B., & Banerjee, S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw142 · Cited by 292
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Johnson, N., Li, Y.-C., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 290
Bang, Y.-J., Im, S.-A., Lee, K.-W., Cho, J. Y., Song, E.-K., Lee, K. H., Kim, Y. H., Park, J. O., Chun, H. G., Zang, D. Y., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0320 · Cited by 290
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2870 · Cited by 281
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
Boulikas, T. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903114168 · Cited by 276
Harnessing synthetic lethal interactions in anticancer drug discovery
Chan, D. A., & Giaccia, A. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3374 · Cited by 262
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Dedes, K. J., Wetterskog, D., Mendes-Pereira, A. M., Natrajan, R., Lambros, M. B., Geyer, F. C., Vatcheva, R., Savage, K., Mackay, A., Lord, C. J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001538 · Cited by 255
Self-citationTrapping Poly(ADP-Ribose) Polymerase
Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Williamson, C. T., Muzik, H., Turhan, A. G., Zamò, A., O'Connor, M. J., Bebb, D. G., & Lees-Miller, S. P. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0872 · Cited by 193
“E-ma gy, Univer Northwest, 403-283-16 doi: 10.115 ©2010 Am www.aacr Poly(ADP-ribose) polymerase-1 (PARP-1) inhibition is toxic to cells with mutations in the breast and ovarian cancer susceptibility genes BRCA1 or BRCA2, a concept termed synthetic lethality.”
BackgroundInfluentialSynthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Dedes, K. J., Wilkerson, P. M., Wetterskog, D., Weigelt, B., Ashworth, A., & Reis-Filho, J. S. (2011) · Cell Cycle · doi:10.4161/cc.10.8.15273 · Cited by 191
Self-citationCisplatin Resistance Associated with PARP Hyperactivation
Michels, J., Vitale, I., Galluzzi, L., Adam, J., Olaussen, K. A., Kepp, O., Senovilla, L., Talhaoui, I., Guegan, J., Enot, D. P., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3000 · Cited by 176
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
George, A., Kaye, S., & Banerjee, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.191 · Cited by 158
PARP Inhibitors in Ovarian Cancer
Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892813666180305165256 · Cited by 158
Effect of ASCO/CAP guidelines for determining ER status on molecular subtype
Deyarmin, B., Kane, J. L., Valente, A. L., van Laar, R., Gallagher, C., Shriver, C. D., & Ellsworth, R. E. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2588-8 · Cited by 149
Bochum, S., Berger, S., & Martens, U. M. (2018) · Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_15 · Cited by 104
Cheng, H., Zhang, Z., Borczuk, A., Powell, C. A., Balajee, A. S., Lieberman, H. B., & Halmos, B. (2013) · Carcinogenesis · doi:10.1093/carcin/bgs393 · Cited by 99
Bundred, N., Gardovskis, J., Jaskiewicz, J., Eglitis, J., Paramonov, V., McCormack, P., Swaisland, H., Cavallin, M., Parry, T., Carmichael, J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9922-7 · Cited by 89
Hereditary breast cancer: From molecular pathology to tailored therapies
Tan, D. S. P., Marchiò, C., & Reis-Filho, J. S. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.057950 · Cited by 60
Targeting DNA damage repair pathways in pancreas cancer
Crowley, F., Park, W., & O’Reilly, E. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09983-1 · Cited by 43
Platinum-based chemotherapy in triple-negative advanced breast cancer
Villarreal-Garza, C., Khalaf, D., Bouganim, N., Clemons, M., Peña-Curiel, O., Baez-Revueltas, B., Kiss, A., Kassam, F., Enright, K., Verma, S., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3033-4 · Cited by 33
Pharmacologic treatment of male breast cancer
Hayes, T. G. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903200634 · Cited by 20
Metadata
- Authors
- Ashworth, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-08-01
- Volume
- 26
- Issue
- 22
- Pages
- 3785-3790
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002962154
- Cited by
- 856
- References
- 63
- FWCI
- 25.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.